1. Farmer, D.G.S., A.M. Ewart, K.M. Mair and S. Kennedy, 2014. Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse. Pulm. Pharmacol. Ther. (In Press). .
2. Almabrouk, T.A.M., A.M. Ewart, I.P. Salt and S. Kennedy, 2014. Perivascular fat, AMP-activated protein kinase and vascular diseases. Br. J. Pharmacol. (In Press). .
   Direct Link  |  
3. Watt, J., S. Kennedy, C.M. McCormick, E.O. Agbani and A. Mullen et al., 2013. Stent-based delivery of succinobucol in a porcine coronary model. Catheter Cardiovasc. Interv., 81: 698-708.
4. McDonald, R.A., K.M. White, J. Wu, B.C. Cooley and K.E. Robertson et al., 2013. miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. Eur. Heart J., 34: 1636-1643.
   CrossRef  |  PubMed  |  
5. Kennedy, S., J. Wu, R.M. Wadsworth, C.E. Lawrence and P. Maffia, 2013. Mast cells and vascular diseases. Pharmacol. Ther., 138: 53-65.
   PubMed  |  
6. Watt, J., F. Greig, M.A. Ewart, R.M. Wadsworth, K.G. Oldroyd and S. Kennedy, 2012. The effect of reactive oxygen species on whole blood aggregation and the endothelial cell-platelet interaction in patients with coronary heart disease. Thromb. Res., 130: 210-215.
   PubMed  |  
7. Greig, F.H., S. Kennedy and C.M. Spickett, 2012. Physiological effects of oxidized phospholipids and their cellular signalling mechanisms in inflammation. Free Radic. Biol. Med., 52: 262-280.
   PubMed  |  
8. Ewart, A.M. and S. Kennedy, 2012. Diabetic cardiovascular disease-AMP-activated protein kinase (AMPK) as a therapeutic target. Cardiovasc. Hematol. Agents Med. Chem., 10: 190-211.
   PubMed  |  
9. Wu, J., R.M. Wadsworth and S. Kennedy, 2011. Inhibition of iNOS promotes vein graft neoadventitial inflammation and remodelling. J. Vasc. Res., 48: 141-149.
   PubMed  |  
10. Ialenti, A., G. Grassia, P. Gordon, M. Maddaluno and M. Vittoria Di Lauro et al., 2011. Inhibition of in-stent restenosis by oral administration of bindarit in porcine coronary artery. Arterioscler. Thromb. Vasc. Biol., 31: 2448-2454.
    PubMed  |  
11. Ewart, A.M. and S. Kennedy, 2011. AMPK and vasculoprotection. Pharmacol. Ther., 131: 242-253.
    PubMed  |  
12. Shedden, L., S. Kennedy, R. Wadsworth and P. Connolly, 2010. Towards a self-reporting coronary artery stent-Measuring neointimal growth associated with in-stent restenosis using electrical impedance techniques. Biosens. Bioelectron., 26: 661-666.
    CrossRef  |  
13. McCormick, C.M., R.L. Jones, S. Kennedy and R.M. Wadsworth, 2010. Activation of prostanoid EP receptors by prostacyclin analogues in rabbit iliac artery: Implications for anti-restenotic potential. Eur. J. Pharmacol., 641: 160-167.
    PubMed  |  
14. Mair, K.M., E. Robinson, K.A. Kane, S. Pyne, N.J. Pyne and S. Kennedy, 2010. Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br. J. Pharmacol., 161: 176-192.
    PubMed  |  
15. Grassia, G., M. Maddaluno, C. Musilli, D. De Stefano and R. Carnuccio et al., 2010. The IκB kinase inhibitor nuclear factor-κB essential modulator-binding domain peptide for inhibition of balloon injury-induced neointimal formation. Arterioscler. Thromb. Vasc. Biol., 30: 2458-2466.
    PubMed  |  
16. Kennedy, S., K.A. Kane, N.J. Pyne and S. Pyne, 2009. Targeting sphingosine-1-phosphate signalling for cardioprotection. Curr. Opinion Pharmacol., 9: 194-201.
    CrossRef  |  PubMed  |  
17. Farmer, D.G. and S. Kennedy, 2009. RAGE, vascular tone and vascular disease. Pharmacol. Ther., 124: 185-194.
    PubMed  |  
18. Watt, J., R.M. Wadsworth, S. Kennedy and K.G. Oldroyd, 2008. Pro-healing drug-eluting stents: A role for antioxidants? Clin. Sci., 114: 265-273.
    PubMed  |  
19. Tennant, G., R.M. Wadsworth and S. Kennedy, 2008. PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse. Atherosclerosis, 198: 57-64.
    PubMed  |  
20. Lim, S.Y., C.L. Wainwright, S. Kennedy and K.A. Kane, 2008. Activation of protease activated receptor-2 induces delayed cardioprotection in anesthetized mice. Cardiovasc. Drugs Ther., 23: 519-520.
    PubMed  |  
21. Erridge, C., S. Kennedy, C.M. Spickett and D.J. Webb, 2008. Oxidised phospholipid inhibition of Toll Like Receptor (TLR) signalling is restricted to TLR2 and TLR4-Roles for CD14, LPS-binding protein and MD2 as targets for specificity of inhibition. J. Biol. Chem., 283: 24748-24759.
    PubMed  |  
22. Coats, P., S. Kennedy, S. Pyne, C.L. Wainwright and R.M. Wadsworth, 2008. Inhibition of non-Ras protein farnesylation reduces in-stent restenosis. Atherosclerosis, 197: 515-523.
    PubMed  |  
23. McCormick, C., R.M. Wadsworth, R.L. Jones and S. Kennedy, 2007. Prostacyclin analogues: The next drug-eluting stent? Biochem. Soc. Trans., 35: 910-911.
    PubMed  |  
24. Maffia, P., B.H. Zinselmeyer, A. Ialenti, S. Kennedy and A.H. Baker et al., 2007. Two-photon microscopy for 3D imaging of lymphocyte recruitment into apolipoprotein E-deficient mouse carotid artery. Circulation, 115: e326-e328.
25. Kennedy, S., S.G. Burke, A.A. Preston and A.R. McPhaden, 2007. Mechanism underlying the increased sensitivity to nitric oxide donor drugs in balloon-injured pig coronary artery. Endothelium, 14: 105-113.
26. Dever, G.J., C.L. Wainwright, S. Kennedy and C.M. Spickett, 2007. Phospholipid chlorohydrin induces leukocyte adhesion to ApoE -/- mouse arteries via upregulation of P-Selectin. Free Radic. Biol. Med., 44: 452-463.
    PubMed  |